Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anticoagulants | 123 | 2024 | 4863 | 11.150 |
Why?
|
Venous Thromboembolism | 72 | 2024 | 1882 | 9.280 |
Why?
|
Thrombosis | 52 | 2024 | 2956 | 8.590 |
Why?
|
Hemorrhage | 47 | 2024 | 3463 | 4.580 |
Why?
|
Heparin | 22 | 2024 | 1632 | 4.430 |
Why?
|
Thrombophilia | 12 | 2021 | 308 | 4.070 |
Why?
|
Warfarin | 18 | 2024 | 1494 | 3.970 |
Why?
|
Heart-Assist Devices | 23 | 2024 | 1297 | 3.840 |
Why?
|
Blood Coagulation Factors | 8 | 2024 | 372 | 3.830 |
Why?
|
Thromboembolism | 18 | 2024 | 1003 | 3.670 |
Why?
|
Factor Xa | 8 | 2024 | 166 | 3.200 |
Why?
|
Thrombocytopenia | 12 | 2023 | 1171 | 2.940 |
Why?
|
International Normalized Ratio | 11 | 2024 | 381 | 2.710 |
Why?
|
Blood Coagulation | 22 | 2024 | 1168 | 2.670 |
Why?
|
Blood Coagulation Disorders | 13 | 2024 | 350 | 2.660 |
Why?
|
Venous Thrombosis | 13 | 2024 | 1327 | 2.590 |
Why?
|
Fibrinolytic Agents | 17 | 2024 | 2082 | 2.450 |
Why?
|
Pregnancy Complications, Hematologic | 10 | 2021 | 184 | 2.370 |
Why?
|
Pyridones | 17 | 2024 | 816 | 2.340 |
Why?
|
Neoplasms | 44 | 2024 | 22350 | 2.290 |
Why?
|
Heparin, Low-Molecular-Weight | 13 | 2024 | 345 | 2.000 |
Why?
|
Vitamin K | 7 | 2024 | 312 | 2.000 |
Why?
|
Nomograms | 5 | 2024 | 235 | 1.960 |
Why?
|
Recombinant Proteins | 12 | 2024 | 6489 | 1.660 |
Why?
|
Blood Coagulation Tests | 10 | 2021 | 263 | 1.630 |
Why?
|
Pyrazoles | 16 | 2024 | 2031 | 1.620 |
Why?
|
Extracorporeal Membrane Oxygenation | 7 | 2024 | 1480 | 1.590 |
Why?
|
Antidotes | 5 | 2019 | 138 | 1.540 |
Why?
|
Pulmonary Embolism | 16 | 2022 | 2600 | 1.470 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 4 | 2024 | 245 | 1.440 |
Why?
|
Dalteparin | 8 | 2024 | 44 | 1.400 |
Why?
|
Fibrin Fibrinogen Degradation Products | 13 | 2022 | 428 | 1.360 |
Why?
|
von Willebrand Diseases | 6 | 2024 | 135 | 1.340 |
Why?
|
Administration, Oral | 26 | 2024 | 4015 | 1.340 |
Why?
|
Premedication | 3 | 2019 | 245 | 1.330 |
Why?
|
Disseminated Intravascular Coagulation | 8 | 2024 | 185 | 1.300 |
Why?
|
Hirudins | 4 | 2017 | 179 | 1.250 |
Why?
|
Humans | 326 | 2024 | 766011 | 1.210 |
Why?
|
Hemostasis | 8 | 2024 | 467 | 1.140 |
Why?
|
Antithrombins | 9 | 2023 | 295 | 1.120 |
Why?
|
Coronavirus Infections | 10 | 2020 | 3099 | 1.120 |
Why?
|
Pneumonia, Viral | 10 | 2020 | 3222 | 1.100 |
Why?
|
Hodgkin Disease | 20 | 2017 | 1383 | 1.030 |
Why?
|
Platelet Aggregation Inhibitors | 13 | 2024 | 2771 | 1.000 |
Why?
|
Hemostatics | 5 | 2023 | 247 | 1.000 |
Why?
|
Partial Thromboplastin Time | 8 | 2024 | 202 | 0.990 |
Why?
|
Myeloproliferative Disorders | 3 | 2024 | 615 | 0.990 |
Why?
|
Hematologic Neoplasms | 5 | 2021 | 1927 | 0.980 |
Why?
|
Atrial Fibrillation | 10 | 2024 | 5188 | 0.910 |
Why?
|
Recurrence | 21 | 2024 | 8505 | 0.900 |
Why?
|
Drug Monitoring | 4 | 2019 | 961 | 0.860 |
Why?
|
Factor XI Deficiency | 2 | 2021 | 16 | 0.850 |
Why?
|
Vaccines | 2 | 2022 | 841 | 0.850 |
Why?
|
Atrial Flutter | 2 | 2024 | 253 | 0.790 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 17 | 2015 | 1435 | 0.780 |
Why?
|
Antiphospholipid Syndrome | 3 | 2024 | 166 | 0.770 |
Why?
|
Blood Component Transfusion | 2 | 2019 | 138 | 0.770 |
Why?
|
Aspirin | 8 | 2023 | 3135 | 0.770 |
Why?
|
Peptide Fragments | 4 | 2017 | 5123 | 0.730 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2024 | 1560 | 0.710 |
Why?
|
Pandemics | 16 | 2024 | 8699 | 0.690 |
Why?
|
Hematology | 2 | 2023 | 243 | 0.690 |
Why?
|
Vasculitis | 2 | 2021 | 523 | 0.680 |
Why?
|
Hemophilia B | 2 | 2023 | 83 | 0.680 |
Why?
|
Muscular Diseases | 1 | 2024 | 550 | 0.670 |
Why?
|
Hemophilia A | 3 | 2023 | 357 | 0.670 |
Why?
|
Red-Cell Aplasia, Pure | 2 | 2018 | 27 | 0.660 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 35 | 2024 | 11862 | 0.650 |
Why?
|
Drug Resistance | 2 | 2024 | 1591 | 0.640 |
Why?
|
Weightlessness | 1 | 2020 | 103 | 0.640 |
Why?
|
Blood Platelet Disorders | 1 | 2019 | 59 | 0.640 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2020 | 187 | 0.640 |
Why?
|
Perioperative Care | 3 | 2024 | 1056 | 0.630 |
Why?
|
Chemoprevention | 1 | 2021 | 327 | 0.630 |
Why?
|
Pyridines | 5 | 2021 | 2889 | 0.630 |
Why?
|
Janus Kinase 2 | 2 | 2021 | 562 | 0.630 |
Why?
|
Sex Reassignment Procedures | 1 | 2019 | 72 | 0.620 |
Why?
|
Designer Drugs | 1 | 2018 | 21 | 0.620 |
Why?
|
Blood Loss, Surgical | 2 | 2019 | 631 | 0.610 |
Why?
|
Stroke | 9 | 2024 | 9750 | 0.590 |
Why?
|
Heart Failure | 13 | 2024 | 11839 | 0.590 |
Why?
|
Blood Group Incompatibility | 1 | 2018 | 134 | 0.580 |
Why?
|
Antibodies, Antiphospholipid | 2 | 2018 | 72 | 0.580 |
Why?
|
Hemoptysis | 1 | 2019 | 150 | 0.580 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 2 | 2018 | 132 | 0.570 |
Why?
|
Risk Adjustment | 1 | 2021 | 596 | 0.570 |
Why?
|
Middle Aged | 112 | 2024 | 223058 | 0.570 |
Why?
|
Benzamides | 4 | 2021 | 1376 | 0.570 |
Why?
|
Risk Factors | 50 | 2024 | 74870 | 0.560 |
Why?
|
Female | 139 | 2024 | 396159 | 0.560 |
Why?
|
Space Flight | 1 | 2020 | 219 | 0.560 |
Why?
|
Vascular System Injuries | 1 | 2020 | 246 | 0.560 |
Why?
|
Male | 131 | 2024 | 363808 | 0.550 |
Why?
|
ABO Blood-Group System | 2 | 2018 | 380 | 0.540 |
Why?
|
Plasma | 2 | 2019 | 579 | 0.530 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2024 | 1127 | 0.530 |
Why?
|
Tranexamic Acid | 1 | 2019 | 174 | 0.520 |
Why?
|
Formularies as Topic | 1 | 2016 | 93 | 0.520 |
Why?
|
beta-Alanine | 2 | 2014 | 83 | 0.520 |
Why?
|
Cannabinoids | 1 | 2018 | 174 | 0.520 |
Why?
|
Extracorporeal Circulation | 1 | 2016 | 182 | 0.510 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2024 | 10389 | 0.510 |
Why?
|
Phenylthiohydantoin | 1 | 2017 | 206 | 0.510 |
Why?
|
Testicular Neoplasms | 2 | 2020 | 802 | 0.500 |
Why?
|
Transsexualism | 1 | 2019 | 210 | 0.500 |
Why?
|
Factor VII Deficiency | 1 | 2015 | 31 | 0.500 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 484 | 0.490 |
Why?
|
Gonadal Steroid Hormones | 1 | 2019 | 704 | 0.490 |
Why?
|
Aged | 76 | 2024 | 171233 | 0.470 |
Why?
|
Adult | 96 | 2024 | 223109 | 0.460 |
Why?
|
Asparaginase | 4 | 2024 | 240 | 0.460 |
Why?
|
Factor XI | 3 | 2024 | 40 | 0.460 |
Why?
|
von Willebrand Factor | 4 | 2024 | 676 | 0.440 |
Why?
|
Intracranial Hemorrhages | 2 | 2018 | 814 | 0.440 |
Why?
|
Vincristine | 21 | 2015 | 1038 | 0.430 |
Why?
|
Retrospective Studies | 43 | 2024 | 81522 | 0.430 |
Why?
|
Risk Assessment | 16 | 2024 | 24299 | 0.430 |
Why?
|
Benzimidazoles | 3 | 2014 | 863 | 0.430 |
Why?
|
Abortion, Habitual | 1 | 2014 | 65 | 0.430 |
Why?
|
Fibrinogen | 3 | 2022 | 897 | 0.420 |
Why?
|
Thiazoles | 2 | 2023 | 1529 | 0.420 |
Why?
|
Antibodies, Monoclonal | 7 | 2018 | 9244 | 0.420 |
Why?
|
Fibrinolysis | 3 | 2024 | 332 | 0.420 |
Why?
|
Emergencies | 1 | 2019 | 1224 | 0.410 |
Why?
|
Epidemics | 1 | 2018 | 513 | 0.410 |
Why?
|
Physician's Role | 1 | 2019 | 927 | 0.400 |
Why?
|
Prostate | 1 | 2021 | 1759 | 0.400 |
Why?
|
British Columbia | 11 | 2017 | 238 | 0.400 |
Why?
|
Vascular Diseases | 1 | 2020 | 1164 | 0.390 |
Why?
|
Drug Costs | 2 | 2019 | 1193 | 0.390 |
Why?
|
Practice Guidelines as Topic | 11 | 2022 | 7426 | 0.380 |
Why?
|
Cardiac Surgical Procedures | 2 | 2024 | 3674 | 0.370 |
Why?
|
Antifibrinolytic Agents | 3 | 2020 | 286 | 0.370 |
Why?
|
Prednisone | 20 | 2015 | 1563 | 0.370 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2018 | 5753 | 0.360 |
Why?
|
Outpatients | 4 | 2022 | 1593 | 0.360 |
Why?
|
Intensive Care Units | 3 | 2022 | 3803 | 0.360 |
Why?
|
Gingival Hemorrhage | 2 | 2009 | 49 | 0.360 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2017 | 844 | 0.360 |
Why?
|
Immunologic Factors | 3 | 2018 | 1585 | 0.350 |
Why?
|
Doxorubicin | 22 | 2017 | 2229 | 0.350 |
Why?
|
Hematologic Diseases | 1 | 2014 | 500 | 0.350 |
Why?
|
Lymphoma, Non-Hodgkin | 11 | 2008 | 1376 | 0.340 |
Why?
|
Treatment Outcome | 38 | 2024 | 65236 | 0.330 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 3251 | 0.330 |
Why?
|
Cyclophosphamide | 22 | 2015 | 2226 | 0.330 |
Why?
|
Hemosiderosis | 1 | 2010 | 66 | 0.330 |
Why?
|
Cost-Benefit Analysis | 3 | 2019 | 5528 | 0.330 |
Why?
|
Cystic Fibrosis | 1 | 2019 | 1287 | 0.330 |
Why?
|
Disease Management | 6 | 2021 | 2534 | 0.320 |
Why?
|
Drug Approval | 1 | 2016 | 818 | 0.320 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2335 | 0.320 |
Why?
|
Platelet Count | 6 | 2023 | 782 | 0.310 |
Why?
|
Ambulatory Care | 3 | 2018 | 2778 | 0.310 |
Why?
|
Neoplasms, Second Primary | 6 | 2022 | 1056 | 0.310 |
Why?
|
Decision Support Systems, Clinical | 1 | 2018 | 1175 | 0.310 |
Why?
|
Myelodysplastic Syndromes | 1 | 2018 | 1404 | 0.300 |
Why?
|
Heart Transplantation | 3 | 2017 | 3310 | 0.300 |
Why?
|
Prognosis | 30 | 2021 | 29915 | 0.300 |
Why?
|
Labor, Obstetric | 1 | 2011 | 316 | 0.290 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6307 | 0.290 |
Why?
|
Prostate-Specific Antigen | 1 | 2017 | 2465 | 0.290 |
Why?
|
Bleomycin | 13 | 2017 | 491 | 0.290 |
Why?
|
Aged, 80 and over | 31 | 2021 | 59526 | 0.290 |
Why?
|
Pregnancy | 17 | 2022 | 30253 | 0.280 |
Why?
|
Registries | 6 | 2021 | 8321 | 0.280 |
Why?
|
Mediastinal Neoplasms | 2 | 2009 | 403 | 0.270 |
Why?
|
Delivery, Obstetric | 2 | 2011 | 946 | 0.270 |
Why?
|
Cardiopulmonary Bypass | 3 | 2024 | 1090 | 0.260 |
Why?
|
Lymphoma, B-Cell | 6 | 2005 | 943 | 0.260 |
Why?
|
Clinical Trials as Topic | 6 | 2022 | 8040 | 0.250 |
Why?
|
Combined Modality Therapy | 22 | 2016 | 8531 | 0.250 |
Why?
|
Enoxaparin | 2 | 2020 | 390 | 0.240 |
Why?
|
Critical Care | 5 | 2024 | 2712 | 0.240 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13455 | 0.240 |
Why?
|
Leukemia, Hairy Cell | 4 | 1998 | 82 | 0.240 |
Why?
|
Drug Administration Schedule | 9 | 2020 | 4850 | 0.230 |
Why?
|
Markov Chains | 2 | 2019 | 967 | 0.230 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2015 | 2136 | 0.230 |
Why?
|
Anesthesia, Obstetrical | 2 | 2021 | 246 | 0.230 |
Why?
|
Whole Blood Coagulation Time | 1 | 2024 | 29 | 0.230 |
Why?
|
Secondary Prevention | 2 | 2021 | 1471 | 0.220 |
Why?
|
Tissue Plasminogen Activator | 2 | 2021 | 1168 | 0.220 |
Why?
|
Prospective Studies | 18 | 2024 | 54818 | 0.220 |
Why?
|
Hospitalization | 7 | 2023 | 10807 | 0.220 |
Why?
|
Bone Marrow Transplantation | 12 | 2000 | 2729 | 0.210 |
Why?
|
Pharmaceutical Preparations | 2 | 2022 | 1083 | 0.210 |
Why?
|
Cardiomyopathies | 2 | 2015 | 2067 | 0.210 |
Why?
|
Polydeoxyribonucleotides | 1 | 2024 | 136 | 0.210 |
Why?
|
Syndrome | 3 | 2022 | 3269 | 0.210 |
Why?
|
Postoperative Hemorrhage | 2 | 2018 | 413 | 0.210 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2004 | 125 | 0.210 |
Why?
|
Lymphoma | 7 | 1997 | 1897 | 0.210 |
Why?
|
Multiple Myeloma | 5 | 2024 | 5196 | 0.210 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2015 | 5336 | 0.200 |
Why?
|
Disease-Free Survival | 11 | 2017 | 6838 | 0.200 |
Why?
|
Lymphoma, Mantle-Cell | 3 | 2017 | 238 | 0.200 |
Why?
|
Heart Ventricles | 4 | 2019 | 3831 | 0.200 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2021 | 10731 | 0.190 |
Why?
|
Sepsis | 3 | 2022 | 2602 | 0.190 |
Why?
|
Antithrombin III Deficiency | 1 | 2021 | 28 | 0.190 |
Why?
|
Incidence | 12 | 2024 | 21507 | 0.190 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 70 | 0.190 |
Why?
|
Quality-Adjusted Life Years | 2 | 2019 | 1739 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2021 | 9371 | 0.180 |
Why?
|
L-Lactate Dehydrogenase | 2 | 2020 | 411 | 0.180 |
Why?
|
Endothelium, Vascular | 3 | 2024 | 4423 | 0.180 |
Why?
|
Transplantation, Autologous | 8 | 2014 | 2126 | 0.180 |
Why?
|
Disease Progression | 7 | 2024 | 13615 | 0.170 |
Why?
|
Costs and Cost Analysis | 2 | 2016 | 1669 | 0.170 |
Why?
|
Prothrombin Time | 1 | 2020 | 116 | 0.170 |
Why?
|
Foramen Ovale, Patent | 1 | 2023 | 211 | 0.170 |
Why?
|
Neoplasm Staging | 13 | 2019 | 11208 | 0.170 |
Why?
|
Transplantation, Homologous | 9 | 2018 | 4858 | 0.170 |
Why?
|
Academic Medical Centers | 4 | 2018 | 2780 | 0.170 |
Why?
|
Pregnancy Complications | 1 | 2014 | 2973 | 0.170 |
Why?
|
Patients | 2 | 2023 | 910 | 0.160 |
Why?
|
Lung Diseases | 1 | 2010 | 1939 | 0.160 |
Why?
|
Antineoplastic Agents | 9 | 2021 | 13639 | 0.160 |
Why?
|
Thiophenes | 1 | 2023 | 570 | 0.160 |
Why?
|
Thrombocythemia, Essential | 1 | 2020 | 114 | 0.160 |
Why?
|
Communication | 2 | 2024 | 3913 | 0.160 |
Why?
|
Etoposide | 10 | 2005 | 636 | 0.160 |
Why?
|
Geriatrics | 1 | 2023 | 395 | 0.160 |
Why?
|
Off-Label Use | 1 | 2020 | 185 | 0.150 |
Why?
|
Illinois | 1 | 2018 | 120 | 0.150 |
Why?
|
Lymphopenia | 1 | 2021 | 297 | 0.150 |
Why?
|
Plasma Exchange | 2 | 2018 | 160 | 0.150 |
Why?
|
Live Birth | 2 | 2020 | 518 | 0.150 |
Why?
|
Hermanski-Pudlak Syndrome | 1 | 2018 | 20 | 0.150 |
Why?
|
Inflammasomes | 1 | 2023 | 544 | 0.150 |
Why?
|
Medication Therapy Management | 1 | 2019 | 131 | 0.150 |
Why?
|
Abortion, Spontaneous | 2 | 2020 | 535 | 0.150 |
Why?
|
Drug and Narcotic Control | 1 | 2019 | 144 | 0.150 |
Why?
|
Comorbidity | 6 | 2024 | 10572 | 0.150 |
Why?
|
Body Weight | 2 | 2019 | 4624 | 0.140 |
Why?
|
Cerebral Hemorrhage | 2 | 2019 | 2649 | 0.140 |
Why?
|
Ferritins | 1 | 2020 | 600 | 0.140 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 1999 | 180 | 0.140 |
Why?
|
Genes, bcl-2 | 1 | 1997 | 119 | 0.140 |
Why?
|
Shock | 1 | 2019 | 316 | 0.140 |
Why?
|
Blood Platelets | 3 | 2023 | 2464 | 0.140 |
Why?
|
Aneurysm, False | 1 | 2019 | 265 | 0.140 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2017 | 86 | 0.130 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2023 | 2423 | 0.130 |
Why?
|
Time Factors | 14 | 2024 | 40117 | 0.130 |
Why?
|
Anemia, Sickle Cell | 1 | 2024 | 1062 | 0.130 |
Why?
|
Leucovorin | 5 | 2005 | 641 | 0.130 |
Why?
|
Clinical Protocols | 4 | 2018 | 1441 | 0.130 |
Why?
|
Vasoconstrictor Agents | 1 | 2019 | 655 | 0.120 |
Why?
|
Intraoperative Care | 1 | 2019 | 764 | 0.120 |
Why?
|
Limit of Detection | 1 | 2016 | 272 | 0.120 |
Why?
|
Gastrointestinal Diseases | 1 | 2024 | 1203 | 0.120 |
Why?
|
Cesarean Section | 3 | 2021 | 1431 | 0.120 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 234 | 0.120 |
Why?
|
Anemia, Aplastic | 1 | 2017 | 231 | 0.120 |
Why?
|
Accidents, Traffic | 1 | 2001 | 818 | 0.120 |
Why?
|
Critical Pathways | 1 | 2019 | 475 | 0.120 |
Why?
|
Vasodilation | 1 | 2019 | 970 | 0.120 |
Why?
|
Algorithms | 4 | 2019 | 14061 | 0.120 |
Why?
|
Patient Selection | 3 | 2021 | 4257 | 0.120 |
Why?
|
Vinblastine | 6 | 2017 | 483 | 0.120 |
Why?
|
Chromatography, Liquid | 1 | 2018 | 991 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2019 | 4057 | 0.120 |
Why?
|
Models, Theoretical | 2 | 2019 | 3563 | 0.120 |
Why?
|
Postoperative Complications | 4 | 2019 | 15803 | 0.120 |
Why?
|
Factor VIII | 2 | 2023 | 347 | 0.110 |
Why?
|
Wounds, Nonpenetrating | 1 | 2001 | 806 | 0.110 |
Why?
|
Adolescent | 29 | 2024 | 88804 | 0.110 |
Why?
|
Bone Neoplasms | 1 | 2006 | 2564 | 0.110 |
Why?
|
Ductus Arteriosus, Patent | 1 | 2016 | 214 | 0.110 |
Why?
|
Extremities | 1 | 2019 | 870 | 0.110 |
Why?
|
Immunoglobulin G | 3 | 2018 | 4526 | 0.110 |
Why?
|
Drug Interactions | 1 | 2018 | 1416 | 0.110 |
Why?
|
Drug Utilization Review | 1 | 2014 | 248 | 0.110 |
Why?
|
Diagnostic Errors | 1 | 2001 | 1277 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2020 | 1622 | 0.110 |
Why?
|
Watchful Waiting | 1 | 2017 | 493 | 0.110 |
Why?
|
Stem Cell Transplantation | 2 | 2014 | 1601 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 4 | 1999 | 1409 | 0.100 |
Why?
|
Propensity Score | 1 | 2021 | 1967 | 0.100 |
Why?
|
Aorta, Thoracic | 1 | 2019 | 1110 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 2 | 2023 | 4521 | 0.100 |
Why?
|
Legislation, Drug | 1 | 2015 | 216 | 0.100 |
Why?
|
Leukocytes | 1 | 2021 | 2027 | 0.100 |
Why?
|
Pilot Projects | 2 | 2024 | 8733 | 0.100 |
Why?
|
Thrombolytic Therapy | 2 | 2021 | 2060 | 0.100 |
Why?
|
Shock, Septic | 1 | 2019 | 772 | 0.100 |
Why?
|
Nuclear Physics | 1 | 2012 | 73 | 0.100 |
Why?
|
Oncology Service, Hospital | 1 | 2012 | 55 | 0.100 |
Why?
|
Health Resources | 1 | 2019 | 949 | 0.100 |
Why?
|
Creatinine | 2 | 2016 | 1917 | 0.100 |
Why?
|
Prosthesis Implantation | 1 | 2017 | 595 | 0.100 |
Why?
|
Young Adult | 9 | 2024 | 59870 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3804 | 0.100 |
Why?
|
Nitriles | 1 | 2017 | 981 | 0.100 |
Why?
|
Postoperative Care | 1 | 2019 | 1475 | 0.100 |
Why?
|
Pharmacists | 1 | 2014 | 261 | 0.100 |
Why?
|
United States | 9 | 2022 | 72914 | 0.100 |
Why?
|
Tandem Mass Spectrometry | 1 | 2018 | 1194 | 0.100 |
Why?
|
Forecasting | 1 | 2021 | 2938 | 0.100 |
Why?
|
Lung Transplantation | 2 | 2018 | 1311 | 0.100 |
Why?
|
Vaccination | 1 | 2024 | 3425 | 0.100 |
Why?
|
Organ Transplantation | 1 | 2022 | 1172 | 0.100 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2016 | 327 | 0.100 |
Why?
|
Hematologic Tests | 2 | 2009 | 239 | 0.100 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2019 | 961 | 0.100 |
Why?
|
Neutrophils | 3 | 2021 | 3771 | 0.090 |
Why?
|
Survival Analysis | 10 | 2020 | 10086 | 0.090 |
Why?
|
Nurses | 2 | 2018 | 2505 | 0.090 |
Why?
|
Survival Rate | 14 | 2009 | 12821 | 0.090 |
Why?
|
Methotrexate | 5 | 2005 | 1721 | 0.090 |
Why?
|
Double-Blind Method | 2 | 2023 | 12433 | 0.090 |
Why?
|
Leukocyte Transfusion | 3 | 2000 | 58 | 0.090 |
Why?
|
Aftercare | 3 | 2022 | 914 | 0.090 |
Why?
|
Age Factors | 5 | 2024 | 18384 | 0.090 |
Why?
|
Arginine | 2 | 2024 | 933 | 0.090 |
Why?
|
Ischemia | 1 | 2019 | 1923 | 0.090 |
Why?
|
Acute Disease | 4 | 2024 | 7238 | 0.090 |
Why?
|
Thrombopoietin | 2 | 2023 | 225 | 0.090 |
Why?
|
Preoperative Care | 1 | 2019 | 2277 | 0.090 |
Why?
|
Anesthesia, Epidural | 2 | 2009 | 239 | 0.090 |
Why?
|
Translocation, Genetic | 3 | 2000 | 1393 | 0.080 |
Why?
|
Cohort Studies | 9 | 2023 | 41652 | 0.080 |
Why?
|
Dental Scaling | 1 | 2009 | 109 | 0.080 |
Why?
|
Drug Hypersensitivity | 1 | 2018 | 903 | 0.080 |
Why?
|
Anesthesia, Spinal | 2 | 2009 | 290 | 0.080 |
Why?
|
Critical Illness | 4 | 2023 | 2746 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2021 | 2185 | 0.080 |
Why?
|
Graft vs Host Disease | 6 | 2017 | 3078 | 0.080 |
Why?
|
Iohexol | 1 | 2010 | 205 | 0.080 |
Why?
|
Procarbazine | 4 | 1997 | 172 | 0.080 |
Why?
|
Lung | 4 | 2022 | 10031 | 0.080 |
Why?
|
Mechlorethamine | 4 | 1997 | 129 | 0.080 |
Why?
|
Disease Outbreaks | 1 | 2018 | 1760 | 0.080 |
Why?
|
Emergency Service, Hospital | 3 | 2023 | 7876 | 0.080 |
Why?
|
Cladribine | 2 | 1998 | 34 | 0.080 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 5 | 2015 | 691 | 0.080 |
Why?
|
Anthracyclines | 1 | 2010 | 284 | 0.080 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2019 | 1755 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3849 | 0.080 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15887 | 0.080 |
Why?
|
Physicians | 2 | 2019 | 4587 | 0.070 |
Why?
|
Dacarbazine | 4 | 2017 | 552 | 0.070 |
Why?
|
Erythropoietin | 1 | 2012 | 716 | 0.070 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2000 | 451 | 0.070 |
Why?
|
Inflammation | 3 | 2023 | 10844 | 0.070 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2014 | 709 | 0.070 |
Why?
|
Health Behavior | 1 | 2019 | 2649 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2018 | 2242 | 0.070 |
Why?
|
Splenectomy | 4 | 1998 | 390 | 0.070 |
Why?
|
Hospitals | 1 | 2021 | 3890 | 0.070 |
Why?
|
Diagnosis, Differential | 5 | 2010 | 12969 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3616 | 0.070 |
Why?
|
Analgesia, Obstetrical | 1 | 2009 | 175 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3655 | 0.070 |
Why?
|
Ultrasonography | 1 | 2020 | 5997 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6508 | 0.070 |
Why?
|
Renal Dialysis | 1 | 2016 | 1801 | 0.070 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39226 | 0.070 |
Why?
|
Wounds and Injuries | 1 | 2019 | 2513 | 0.070 |
Why?
|
Pregnancy Outcome | 1 | 2017 | 2969 | 0.070 |
Why?
|
Lymphoma, Follicular | 1 | 2010 | 459 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3278 | 0.060 |
Why?
|
Vascular Surgical Procedures | 1 | 2014 | 1516 | 0.060 |
Why?
|
Predictive Value of Tests | 7 | 2022 | 15403 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3926 | 0.060 |
Why?
|
Infant, Premature | 1 | 2015 | 2120 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2823 | 0.060 |
Why?
|
Patient Readmission | 1 | 2019 | 3286 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2020 | 3641 | 0.060 |
Why?
|
Databases as Topic | 1 | 2006 | 472 | 0.060 |
Why?
|
Stomatitis | 1 | 1987 | 270 | 0.060 |
Why?
|
Age Distribution | 4 | 2011 | 2865 | 0.060 |
Why?
|
Models, Biological | 1 | 2020 | 9439 | 0.060 |
Why?
|
Child | 11 | 2021 | 80510 | 0.060 |
Why?
|
Actuarial Analysis | 3 | 1997 | 368 | 0.060 |
Why?
|
Interferon Type I | 2 | 1985 | 567 | 0.060 |
Why?
|
Patient Discharge | 3 | 2022 | 3466 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 2 | 2023 | 3737 | 0.050 |
Why?
|
Living Donors | 1 | 2008 | 645 | 0.050 |
Why?
|
Clinical Competence | 1 | 2019 | 4863 | 0.050 |
Why?
|
Blood Transfusion | 1 | 1990 | 1295 | 0.050 |
Why?
|
Acute Kidney Injury | 1 | 2016 | 1946 | 0.050 |
Why?
|
Radiography, Thoracic | 1 | 2010 | 1315 | 0.050 |
Why?
|
Platelet Aggregation | 2 | 2020 | 770 | 0.050 |
Why?
|
Stromal Cells | 1 | 2008 | 1332 | 0.050 |
Why?
|
Myocardial Infarction | 2 | 2023 | 11506 | 0.050 |
Why?
|
Biopsy | 4 | 2010 | 6766 | 0.050 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1788 | 0.050 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 1985 | 297 | 0.050 |
Why?
|
Tumor Virus Infections | 1 | 1985 | 438 | 0.050 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 266 | 0.050 |
Why?
|
Graft vs Tumor Effect | 2 | 1999 | 70 | 0.050 |
Why?
|
Transients and Migrants | 1 | 2005 | 170 | 0.050 |
Why?
|
Radiotherapy | 2 | 2006 | 1494 | 0.050 |
Why?
|
Lymphoma, Large-Cell, Immunoblastic | 2 | 2002 | 25 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20125 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2018 | 22230 | 0.050 |
Why?
|
Body Mass Index | 2 | 2019 | 13044 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5440 | 0.050 |
Why?
|
Celiac Disease | 1 | 2010 | 820 | 0.050 |
Why?
|
Prosthesis Design | 2 | 2019 | 2112 | 0.050 |
Why?
|
Genes, myc | 2 | 2000 | 392 | 0.050 |
Why?
|
Bone Marrow | 6 | 1997 | 2919 | 0.050 |
Why?
|
Mutation | 2 | 2021 | 30187 | 0.050 |
Why?
|
Central Nervous System Neoplasms | 1 | 2009 | 918 | 0.050 |
Why?
|
Drug Evaluation | 2 | 2014 | 641 | 0.050 |
Why?
|
Multivariate Analysis | 7 | 2008 | 12060 | 0.050 |
Why?
|
Medical Records | 1 | 2006 | 1409 | 0.050 |
Why?
|
Medicare | 1 | 2019 | 6821 | 0.040 |
Why?
|
Inappropriate Prescribing | 1 | 2023 | 211 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2024 | 15647 | 0.040 |
Why?
|
Life Tables | 2 | 1998 | 366 | 0.040 |
Why?
|
Interferon-alpha | 3 | 1999 | 910 | 0.040 |
Why?
|
Leukocyte Count | 3 | 2021 | 1603 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 14645 | 0.040 |
Why?
|
Infant, Newborn | 6 | 2017 | 26341 | 0.040 |
Why?
|
Ohio | 1 | 2001 | 320 | 0.040 |
Why?
|
Transplantation Conditioning | 3 | 2008 | 1635 | 0.040 |
Why?
|
Embryonic and Fetal Development | 1 | 2001 | 419 | 0.040 |
Why?
|
Traumatology | 1 | 2001 | 101 | 0.040 |
Why?
|
PubMed | 1 | 2020 | 130 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2021 | 404 | 0.040 |
Why?
|
Birth Weight | 2 | 2015 | 2122 | 0.040 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2021 | 113 | 0.040 |
Why?
|
Lymphoma, T-Cell | 2 | 1999 | 308 | 0.040 |
Why?
|
Maternal Mortality | 1 | 2022 | 311 | 0.040 |
Why?
|
Multicenter Studies as Topic | 2 | 2018 | 1731 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 1985 | 1078 | 0.040 |
Why?
|
Maternal Age | 1 | 2022 | 804 | 0.040 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2001 | 271 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3854 | 0.040 |
Why?
|
Utah | 1 | 2019 | 130 | 0.040 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2020 | 153 | 0.040 |
Why?
|
Centrifugation | 1 | 2019 | 121 | 0.040 |
Why?
|
Postal Service | 1 | 1979 | 96 | 0.040 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2001 | 416 | 0.040 |
Why?
|
Pentostatin | 1 | 1998 | 26 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 416 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2017 | 2229 | 0.040 |
Why?
|
Catheters | 1 | 2021 | 426 | 0.040 |
Why?
|
Autopsy | 1 | 2022 | 1012 | 0.040 |
Why?
|
Patient Advocacy | 1 | 2021 | 361 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 1999 | 247 | 0.040 |
Why?
|
Quality of Life | 4 | 2023 | 13470 | 0.040 |
Why?
|
Cause of Death | 2 | 2022 | 3710 | 0.040 |
Why?
|
France | 1 | 2019 | 495 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2020 | 682 | 0.040 |
Why?
|
Urinalysis | 1 | 2000 | 370 | 0.040 |
Why?
|
Sus scrofa | 1 | 2020 | 430 | 0.040 |
Why?
|
Megakaryocytes | 1 | 2022 | 557 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2006 | 3538 | 0.040 |
Why?
|
Thrombin | 1 | 2021 | 603 | 0.040 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 1999 | 322 | 0.040 |
Why?
|
Burkitt Lymphoma | 1 | 2000 | 338 | 0.040 |
Why?
|
Infusion Pumps | 1 | 2019 | 163 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 713 | 0.040 |
Why?
|
Lactation Disorders | 1 | 2017 | 14 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2021 | 3584 | 0.040 |
Why?
|
Diagnostic Imaging | 3 | 2000 | 3527 | 0.040 |
Why?
|
Gender Identity | 1 | 2023 | 767 | 0.040 |
Why?
|
Pulmonary Edema | 1 | 2020 | 412 | 0.040 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2019 | 236 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2023 | 1027 | 0.040 |
Why?
|
Receptors, Fc | 1 | 2021 | 536 | 0.040 |
Why?
|
Injury Severity Score | 1 | 2001 | 1049 | 0.030 |
Why?
|
Sex Distribution | 2 | 1999 | 2268 | 0.030 |
Why?
|
Emergency Treatment | 1 | 2001 | 494 | 0.030 |
Why?
|
Medication Errors | 1 | 2023 | 786 | 0.030 |
Why?
|
Treatment Failure | 2 | 2015 | 2654 | 0.030 |
Why?
|
Nurse's Role | 1 | 2018 | 187 | 0.030 |
Why?
|
Lymphoproliferative Disorders | 1 | 2000 | 526 | 0.030 |
Why?
|
Contrast Media | 1 | 2010 | 5330 | 0.030 |
Why?
|
Fatal Outcome | 2 | 2017 | 1834 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2017 | 570 | 0.030 |
Why?
|
Vena Cava Filters | 1 | 2019 | 272 | 0.030 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1999 | 689 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2020 | 1589 | 0.030 |
Why?
|
Microvessels | 1 | 2020 | 589 | 0.030 |
Why?
|
Gene Expression | 1 | 2008 | 7583 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2021 | 1186 | 0.030 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 622 | 0.030 |
Why?
|
Gene Rearrangement | 2 | 1999 | 1144 | 0.030 |
Why?
|
Ticlopidine | 1 | 2000 | 732 | 0.030 |
Why?
|
Fetal Death | 1 | 2017 | 434 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2001 | 1776 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2006 | 2894 | 0.030 |
Why?
|
Stockings, Compression | 1 | 2015 | 37 | 0.030 |
Why?
|
Organization and Administration | 1 | 2014 | 54 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.030 |
Why?
|
Necrosis | 1 | 2019 | 1613 | 0.030 |
Why?
|
Chorionic Villi | 1 | 2015 | 53 | 0.030 |
Why?
|
Phenotype | 2 | 2023 | 16707 | 0.030 |
Why?
|
Drug Substitution | 1 | 2017 | 292 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5368 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1998 | 646 | 0.030 |
Why?
|
Interferons | 1 | 1998 | 714 | 0.030 |
Why?
|
Immunoglobulin M | 2 | 2018 | 1527 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2000 | 805 | 0.030 |
Why?
|
Carmustine | 4 | 1999 | 137 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2019 | 958 | 0.030 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 503 | 0.030 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2000 | 617 | 0.030 |
Why?
|
Fetal Blood | 1 | 2001 | 1369 | 0.030 |
Why?
|
Pregnancy, Multiple | 1 | 2015 | 216 | 0.030 |
Why?
|
Hemostatic Techniques | 1 | 2014 | 115 | 0.030 |
Why?
|
Hematoma | 1 | 2018 | 766 | 0.030 |
Why?
|
Piperazines | 1 | 2024 | 2546 | 0.030 |
Why?
|
Pharmacy Service, Hospital | 1 | 2014 | 134 | 0.030 |
Why?
|
China | 1 | 2020 | 2387 | 0.030 |
Why?
|
Drug Industry | 1 | 2020 | 791 | 0.030 |
Why?
|
Sex Factors | 2 | 2019 | 10605 | 0.030 |
Why?
|
Nuclear Energy | 1 | 2012 | 15 | 0.030 |
Why?
|
Anemia, Refractory | 1 | 1992 | 17 | 0.030 |
Why?
|
Bone Marrow Purging | 1 | 1993 | 108 | 0.030 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2001 | 1936 | 0.030 |
Why?
|
Infant, Very Low Birth Weight | 1 | 2016 | 409 | 0.030 |
Why?
|
Leptin | 1 | 2001 | 1597 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2008 | 9521 | 0.030 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2019 | 888 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2023 | 3504 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3200 | 0.030 |
Why?
|
Telomerase | 1 | 2017 | 749 | 0.020 |
Why?
|
Antithrombin Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1461 | 0.020 |
Why?
|
Fluid Therapy | 1 | 2016 | 585 | 0.020 |
Why?
|
Anemia, Sideroblastic | 1 | 1992 | 106 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2017 | 20676 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2001 | 1845 | 0.020 |
Why?
|
Canada | 1 | 1997 | 2119 | 0.020 |
Why?
|
Hyperlipoproteinemias | 1 | 1991 | 19 | 0.020 |
Why?
|
Serotonin | 1 | 2016 | 1047 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 1999 | 6062 | 0.020 |
Why?
|
Europe | 1 | 2018 | 3427 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2020 | 1885 | 0.020 |
Why?
|
Infertility, Female | 1 | 2017 | 763 | 0.020 |
Why?
|
Gestational Age | 2 | 2016 | 3615 | 0.020 |
Why?
|
Karyotyping | 3 | 1999 | 1176 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2016 | 1669 | 0.020 |
Why?
|
Economics, Pharmaceutical | 1 | 2011 | 88 | 0.020 |
Why?
|
Salvage Therapy | 1 | 1997 | 1272 | 0.020 |
Why?
|
Renal Insufficiency | 1 | 2016 | 808 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2015 | 621 | 0.020 |
Why?
|
Terminology as Topic | 1 | 1997 | 1536 | 0.020 |
Why?
|
Leukapheresis | 1 | 1990 | 150 | 0.020 |
Why?
|
Infant, Premature, Diseases | 1 | 2016 | 712 | 0.020 |
Why?
|
Hypergammaglobulinemia | 1 | 2009 | 70 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2000 | 5501 | 0.020 |
Why?
|
Databases, Factual | 2 | 2021 | 8062 | 0.020 |
Why?
|
Arizona | 1 | 1989 | 108 | 0.020 |
Why?
|
Mortality | 1 | 2021 | 2910 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2016 | 2350 | 0.020 |
Why?
|
Autoantibodies | 1 | 2018 | 2112 | 0.020 |
Why?
|
Hepatitis C | 1 | 1999 | 1596 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3051 | 0.020 |
Why?
|
Immunophenotyping | 3 | 1999 | 1865 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2001 | 3687 | 0.020 |
Why?
|
Inpatients | 1 | 2020 | 2565 | 0.020 |
Why?
|
Age of Onset | 1 | 2016 | 3341 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2000 | 1644 | 0.020 |
Why?
|
Stomach Neoplasms | 1 | 1999 | 1468 | 0.020 |
Why?
|
Lymphatic Metastasis | 2 | 1999 | 2883 | 0.020 |
Why?
|
Medication Adherence | 1 | 2020 | 2190 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4752 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2009 | 18065 | 0.020 |
Why?
|
Genes, MHC Class II | 1 | 2008 | 433 | 0.020 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 1988 | 179 | 0.020 |
Why?
|
RNA | 1 | 2017 | 2716 | 0.020 |
Why?
|
Protons | 1 | 2012 | 1071 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2012 | 1238 | 0.020 |
Why?
|
Length of Stay | 1 | 2001 | 6492 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 1997 | 11036 | 0.020 |
Why?
|
Kidney | 1 | 2022 | 7073 | 0.020 |
Why?
|
Remission Induction | 3 | 1999 | 2409 | 0.020 |
Why?
|
Triiodothyronine | 1 | 1988 | 493 | 0.020 |
Why?
|
Prevalence | 2 | 2020 | 15833 | 0.020 |
Why?
|
Risk | 1 | 1998 | 9600 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2014 | 1672 | 0.020 |
Why?
|
Logistic Models | 1 | 2001 | 13271 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1325 | 0.020 |
Why?
|
Orchiectomy | 1 | 1988 | 465 | 0.020 |
Why?
|
Germinal Center | 1 | 2008 | 379 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2269 | 0.020 |
Why?
|
Pediatrics | 1 | 2001 | 3604 | 0.020 |
Why?
|
Data Collection | 1 | 2014 | 3318 | 0.020 |
Why?
|
Acute Coronary Syndrome | 1 | 2018 | 2185 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12520 | 0.020 |
Why?
|
Siblings | 1 | 2009 | 828 | 0.010 |
Why?
|
Phorbols | 1 | 1984 | 44 | 0.010 |
Why?
|
Thyroxine | 1 | 1988 | 665 | 0.010 |
Why?
|
Mass Screening | 1 | 2020 | 5448 | 0.010 |
Why?
|
Phorbol Esters | 1 | 1984 | 108 | 0.010 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1985 | 239 | 0.010 |
Why?
|
Hospitals, General | 1 | 2008 | 802 | 0.010 |
Why?
|
Poisson Distribution | 1 | 2005 | 508 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 2004 | 284 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2687 | 0.010 |
Why?
|
Nausea | 1 | 1985 | 679 | 0.010 |
Why?
|
Leukemia | 2 | 1999 | 1523 | 0.010 |
Why?
|
Palliative Care | 1 | 1997 | 3646 | 0.010 |
Why?
|
Vomiting | 1 | 1985 | 646 | 0.010 |
Why?
|
Anesthesia, General | 1 | 2009 | 1174 | 0.010 |
Why?
|
Child, Preschool | 4 | 2011 | 42481 | 0.010 |
Why?
|
Carcinogens | 1 | 1984 | 451 | 0.010 |
Why?
|
Libido | 1 | 1982 | 123 | 0.010 |
Why?
|
Smoking | 1 | 1998 | 9082 | 0.010 |
Why?
|
Classification | 1 | 2002 | 128 | 0.010 |
Why?
|
Thyroid Gland | 1 | 1988 | 1169 | 0.010 |
Why?
|
Epidermal Growth Factor | 1 | 1984 | 698 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2008 | 1726 | 0.010 |
Why?
|
Cisplatin | 2 | 1999 | 1656 | 0.010 |
Why?
|
Bacteriuria | 1 | 2000 | 102 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 1997 | 10262 | 0.010 |
Why?
|
Crohn Disease | 1 | 1992 | 2284 | 0.010 |
Why?
|
Infant | 3 | 2011 | 36377 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 4109 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1999 | 5838 | 0.010 |
Why?
|
Urine | 1 | 2000 | 362 | 0.010 |
Why?
|
Whole-Body Irradiation | 1 | 2000 | 438 | 0.010 |
Why?
|
Lymph Nodes | 3 | 1997 | 3449 | 0.010 |
Why?
|
Chromosome Aberrations | 2 | 1997 | 1776 | 0.010 |
Why?
|
Analysis of Variance | 2 | 2001 | 6209 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 2630 | 0.010 |
Why?
|
Prednisolone | 1 | 1999 | 323 | 0.010 |
Why?
|
Thyroid Neoplasms | 1 | 1991 | 2354 | 0.010 |
Why?
|
Trisomy | 1 | 1999 | 259 | 0.010 |
Why?
|
Chimera | 1 | 1999 | 455 | 0.010 |
Why?
|
Blood Grouping and Crossmatching | 1 | 1998 | 99 | 0.010 |
Why?
|
Hypothyroidism | 1 | 1982 | 665 | 0.010 |
Why?
|
Papillary Muscles | 1 | 1978 | 192 | 0.010 |
Why?
|
Platelet Transfusion | 1 | 2000 | 296 | 0.010 |
Why?
|
Mitotic Index | 1 | 1997 | 160 | 0.010 |
Why?
|
Antigens, CD20 | 1 | 1997 | 198 | 0.010 |
Why?
|
bcl-2-Associated X Protein | 1 | 1997 | 283 | 0.010 |
Why?
|
Proto-Oncogenes | 1 | 1997 | 320 | 0.010 |
Why?
|
Infertility | 1 | 1982 | 656 | 0.010 |
Why?
|
Radiation Injuries | 1 | 1982 | 1181 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 1984 | 2817 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1985 | 4884 | 0.010 |
Why?
|
Chromosome Disorders | 1 | 1997 | 498 | 0.010 |
Why?
|
Menopause | 1 | 1982 | 1661 | 0.010 |
Why?
|
Safety | 1 | 1999 | 1158 | 0.010 |
Why?
|
Epirubicin | 1 | 1993 | 82 | 0.010 |
Why?
|
Graft vs Host Reaction | 1 | 1993 | 99 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 1985 | 3210 | 0.010 |
Why?
|
Animals | 3 | 2020 | 168721 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 1997 | 679 | 0.010 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 1997 | 614 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 1997 | 616 | 0.010 |
Why?
|
Hydrocortisone | 1 | 2001 | 1832 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2008 | 8602 | 0.010 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 1992 | 127 | 0.010 |
Why?
|
Busulfan | 1 | 1993 | 264 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 1985 | 4779 | 0.010 |
Why?
|
Melphalan | 1 | 1993 | 425 | 0.010 |
Why?
|
Cytarabine | 1 | 1993 | 697 | 0.010 |
Why?
|
Apolipoproteins B | 1 | 1991 | 384 | 0.010 |
Why?
|
Hypertension | 1 | 2009 | 8627 | 0.010 |
Why?
|
Tissue Donors | 1 | 1999 | 2393 | 0.000 |
Why?
|
Graft Survival | 1 | 2000 | 3897 | 0.000 |
Why?
|
Immunotherapy, Adoptive | 1 | 1999 | 1511 | 0.000 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1997 | 1534 | 0.000 |
Why?
|
Radiography | 1 | 1999 | 6938 | 0.000 |
Why?
|
Probability | 1 | 1993 | 2475 | 0.000 |
Why?
|
Periodicals as Topic | 1 | 1979 | 1462 | 0.000 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1997 | 2839 | 0.000 |
Why?
|
Radioimmunoassay | 1 | 1988 | 860 | 0.000 |
Why?
|
Stem Cells | 1 | 2000 | 3539 | 0.000 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 4208 | 0.000 |
Why?
|
Rats, Inbred Strains | 1 | 1988 | 2077 | 0.000 |
Why?
|
Insulin | 1 | 2001 | 6598 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 1983 | 4904 | 0.000 |
Why?
|
Hemoglobins | 1 | 1991 | 1529 | 0.000 |
Why?
|
Immunoglobulin D | 1 | 1985 | 55 | 0.000 |
Why?
|
Immunochemistry | 1 | 1985 | 116 | 0.000 |
Why?
|
Dexamethasone | 1 | 1993 | 1964 | 0.000 |
Why?
|
Kidney Transplantation | 1 | 2000 | 4268 | 0.000 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 1985 | 84 | 0.000 |
Why?
|
Echocardiography | 1 | 1978 | 5042 | 0.000 |
Why?
|
Regional Blood Flow | 1 | 1988 | 1481 | 0.000 |
Why?
|
Antibodies | 1 | 1991 | 2416 | 0.000 |
Why?
|
Genotype | 1 | 1997 | 13024 | 0.000 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1983 | 355 | 0.000 |
Why?
|
Immunoenzyme Techniques | 1 | 1985 | 1697 | 0.000 |
Why?
|
Tyrosine | 1 | 1984 | 1427 | 0.000 |
Why?
|
Protein Kinase C | 1 | 1984 | 1202 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 1999 | 26283 | 0.000 |
Why?
|
Amino Acids | 1 | 1984 | 1709 | 0.000 |
Why?
|
Heart Murmurs | 1 | 1978 | 92 | 0.000 |
Why?
|
Rupture, Spontaneous | 1 | 1978 | 359 | 0.000 |
Why?
|
Protein Kinases | 1 | 1984 | 1611 | 0.000 |
Why?
|
Uremia | 1 | 1978 | 202 | 0.000 |
Why?
|
Kinetics | 1 | 1984 | 6261 | 0.000 |
Why?
|
Cell Nucleus | 1 | 1985 | 2864 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 1983 | 21062 | 0.000 |
Why?
|
Killer Cells, Natural | 1 | 1983 | 2207 | 0.000 |
Why?
|
Phosphorylation | 1 | 1984 | 8279 | 0.000 |
Why?
|
Rats | 1 | 1988 | 23702 | 0.000 |
Why?
|
Cell Line | 1 | 1984 | 15541 | 0.000 |
Why?
|
Heart Valve Prosthesis | 1 | 1978 | 1466 | 0.000 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1984 | 4046 | 0.000 |
Why?
|
Mitral Valve Insufficiency | 1 | 1978 | 1414 | 0.000 |
Why?
|